Chardan analyst Rudy Li initiated coverage of Immunic (IMUX) with a Buy rating and $13 price target The firm cites the potential of the company’s lead asset IMU-838 for the treatment of multiple sclerosis for the Buy rating. The drug has a good chance to report positive data from the ongoing Phase 3 studies, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX:
- Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Amid Promising MS Trial Results
- Immunic Presents Promising Phase 2 Trial Results
- Immunic receives notice of allowance for vidofludimus calcium patent
- Promising Efficacy and Safety of Vidofludimus Calcium in MS Trials Reinforces Buy Rating
- Immunic, Inc. Advances Multiple Sclerosis Drug Trials